Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,629 | 214 | 1,390 |
| Samples | 433 | 80 | 345 |
| Peptides | 324 | 57 | 282 |
Function
MMP2 · Matrix metallopeptidase 2
This gene is a member of the matrix metalloproteinase (MMP) gene family, that are zinc-dependent enzymes capable of cleaving components of the extracellular matrix and molecules involved in signal transduction. The protein encoded by this gene is a gelatinase A, type IV collagenase, that contains three fibronectin type II repeats in its catalytic site that allow binding of denatured type IV and V collagen and elastin. Unlike most MMP family members, activation of this protein can occur on the cell membrane. This enzyme can be activated extracellularly by proteases, or, intracellulary by its S-glutathiolation with no requirement for proteolytical removal of the pro-domain. This protein is thought to be involved in multiple pathways including roles in the nervous system, endometrial menstrual breakdown, regulation of vascularization, and metastasis. Mutations in this gene have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2014].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 313 amino-acid changes on canonical ENST00000219070 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MMP2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MMP2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 17/304 6% | 33/1390 2% |
| Endometrial Carcinoma | 2/42 5% | 15/612 2% |
| Melanoma | 4/210 2% | 47/1899 2% |
| Colorectal Carcinoma | 17/143 12% | 63/3239 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Cervical Carcinoma | 1/35 3% | 9/422 2% |
| Gastric Carcinoma | 1/74 1% | 26/1809 1% |
| Bladder Carcinoma | 0/58 0% | 13/956 1% |
| Other Solid Cancers | 3/94 3% | 14/1515 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 7/810 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 5/752 1% |
| Ovarian Carcinoma | 4/109 4% | 6/998 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Head and Neck Carcinoma | 1/85 1% | 13/1574 1% |
| Neuroendocrine Tumour | 4/154 3% | 2/577 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
| Kidney Carcinoma | 3/85 4% | 8/1862 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 12/2550 0% |
| Glioma | 0/52 0% | 10/2127 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Breast Carcinoma | 1/144 1% | 14/3264 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 7/1592 0% |
| Hepatocellular Carcinoma | 1/46 2% | 8/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 9/2534 0% |
Mutation Distribution
Where MMP2 is mutated · all tissues, split by cell line vs tissue
How many mutations in MMP2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,629 mutations in MMP2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|